A density gradient of basement membrane laminins modulates retinal pigment epithelium contractility levels by differential ...

The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration ...

gcl, ganglion cell layer; inl, inner nuclear layer ... was used to remove the cornea, iris, sclera and retinal pigment epithelium. Retinas were homogenized using TRIzol (Thermo Fisher Scientific; ...

A personalized gene editing therapy was successfully used to treat an infant with CPS1 deficiency, a disease that causes ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M.

In the month of March, not only did trials progress, but approvals for new and expanded uses of treatments were issued.

Macular degeneration usually refers to the age-related degenerative changes in the retina that can result in loss of central vision. It is caused by abnormal blood vessel growth (a condition ...